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Abstract The long-term administration of L-carnitine was very
effective in preventing cardiomegaly in juvenile visceral steatosis
(JVS) mice, which was confirmed by heart weight as well as the
lipid contents in heart tissue. After i.p. injection of L-carnitine,
the concentration of free carnitine in heart remained constant,
although serum free carnitine level increased up to 80-fold. On
the other hand, a significant increase in short-chain acyl-
carnitine level in heart was observed. These results suggest that
increased levels of short-chain acyl-carnitine, not free carnitine,
might be a key compound in the protective effect of L-carnitine
administration in JVS mice.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
In primary carnitine de¢ciency, cardiomegaly is a common
symptom. Heart carnitine levels in untreated patients are
lower than those in normals and the oral administration of
L-carnitine reduces cardiomegaly. During such a treatment, it
would be expected that the carnitine level in heart would be
corrected when the serum carnitine concentration is restored
to normal [1^7]. However, there are, in fact, no data to sup-
port this conclusion.
Juvenile visceral steatosis (JVS) mice, discovered in 1988,
are currently thought to serve as a valuable animal model for
primary carnitine de¢ciency [8^11]. Heart carnitine levels are
low in JVS mice and they show cardiomegaly which responds
to L-carnitine treatment [12^17]. These ¢ndings for JVS mice
are identical to the reported features of primary carnitine
de¢ciency in humans.
The present study was undertaken to examine the issue of
whether or not heart carnitine levels are altered as a result of
L-carnitine treatment.
2. Materials and methods
2.1. Animals
The JVS mice used were B6/JVS mice [18,19], which were obtained
by back-crossing the autosomal recessive mutant gene from C3H/JVS
mice [9]. C57BL/6J mice served as controls. All animals were main-
tained under speci¢c pathogen-free conditions.
JVS and control mice were studied at 2, 4 and 8 weeks of age for
long-term experiments. Most JVS mice died within 5 weeks after birth
unless they had received an intraperitoneal injection of L-carnitine.
Thus, the mice were killed at 4 weeks after birth (JVS/N at 4 weeks
group). Since only a small number of animals survived to 8 weeks if
they did not receive treatment, L-carnitine was injected intraperito-
neally at a dose of 1 Wmol/g body weight every morning from 10 to
20^25 days after birth. The animals were killed at 8 weeks without
subsequent injection (JVS/N at 8 weeks group). For the animals in the
treatment group, intraperitoneal injection of L-carnitine which began
from day 10 after birth was continued until they were killed at 4 or
8 weeks (JVS/T at 4 weeks and JVS/T at 8 weeks, respectively). For
the short-term experiments after intraperitoneal injections of L-carni-
tine, mice aged 8^9 weeks were used. The heart was removed after an
injection of sodium pentobarbital (50 Wg/g i.p.), immediately frozen in
liquid nitrogen and stored until use.
The heart weight and the body weight were determined and the
heart weight relative to body weight was calculated.
2.2. Carnitine levels in heart during L-carnitine treatment
The hearts of the JVS mice were removed at ages 2, 4 or 8 weeks
24 h after an intraperitoneal injection of L-carnitine. The heart carni-
tine levels were determined in order to analyze the long-term e¡ect of
L-carnitine treatment.
2.3. Acute change of carnitine levels in serum and heart after an
intraperitoneal injection of L-carnitine
After an intraperitoneal injection of L-carnitine at a dose of 1 Wmol/g
body weight, blood was collected from cut tails. The time points were
3, 5, 7, 9, 11, 13, 15, 22.5, 30 and 45 min, 1, 2 and 4 h (all times
accurate to þ 30 s). Serum was separated and its free carnitine levels
were determined. The time course of free carnitine levels in blood was
analyzed by a one-compartment model with ¢rst order absorption
[20]. To analyze the change of carnitine concentration in heart after
L-carnitine injection, the hearts were removed at 15 and 30 min by the
following method.
After an L-carnitine injection, at 8 min, sodium pentobarbital
(50 Wg/g) was injected intraperitoneally. At 11 min, heparin (30 unit/
30 Wl) was injected into the femoral vein to prevent blood coagulation.
At 14 min, cold saline (4‡C) was infused from the left ventricle to
wash the heart in situ for 1 min [21], and the heart was immediately
removed and placed in liquid nitrogen.
After an L-carnitine injection, pentobarbital was injected at 23 min,
heparin was injected at 26 min, cold saline was infused at 29 min for
1 min and the heart was treated as described above.
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2.4. Biochemical analysis
Free carnitine levels in serum were measured by radioisotope assay
and photometric assay using a carnitine assay kit [22,23]. Heart was
extracted with 6% perchloric acid [17]. The acid-soluble fraction was
used for the determination of free carnitine and short-chain acyl-car-
nitine. The acid-insoluble fraction was used for the determination of
long-chain acyl-carnitine [22,24]. Then both these acyl-carnitine frac-
tions were treated with alkaline, and the free carnitine was assayed
spectrophotometrically. Folch’s method was used to extract lipids
from the heart [25]. Total lipid, triacylglycerol, total cholesterol and
total phospholipid were quanti¢ed using Inui’s method [26]. Phospho-
lipid fractions were quanti¢ed using two-dimensional thin-layer chro-
matography [27].
2.5. Reagents
L-Carnitine (L-hydroxy-trimethylaminobutyric acid) was obtained
from Sigma Chemical Co. (St. Louis, MO, USA). All other chemicals
were of reagent grade and obtained from Sigma or Wako (Osaka,
Japan). The carnitine assay kit was purchased from Kainos (Japan).
2.6. Statistics
Results are expressed as mean þ S.D. Di¡erences between the two
groups were tested by the unpaired t-test, and di¡erences among the
three groups were tested by one-way ANOVA (analysis of variance)
followed by post hoc Fisher’s PLSD. Replicated measurements were
analyzed by repeated ANOVA. A value of P6 0.05 was considered to
be statistically signi¢cant.
3. Results
3.1. E¡ects of L-carnitine treatment on heart weight, body
weight and the heart weight/body weight ratio
The heart weights at ages 2 and 8 weeks were signi¢cantly
greater in untreated JVS mice than in control mice (Table 1).
Cardiomegaly was less marked in treated JVS mice than in
untreated JVS mice after 8 weeks of treatment.
The heart weight at age 4 weeks was lower in the untreated
JVS mouse group than in the control group and the treated
JVS mouse group. Treatment of JVS mice with L-carnitine
resulted in a fall in heart weight to a level which was still
signi¢cantly di¡erent from that of the control group at
8 weeks.
The body weights of the untreated JVS mouse group at ages
4 and 8 weeks were signi¢cantly lower than those of the con-
trol group. Treatment of JVS mice with L-carnitine resulted in
a signi¢cant increase in body weight in comparison with un-
treated JVS mice. The heart weight/body weight ratio, which
is an indicator of cardiomegaly, at ages 2, 4 and 8 weeks was
signi¢cantly higher in the untreated JVS mouse group than in
the control group. This ratio decreased after 4 and 8 weeks of
treatment with L-carnitine.
3.2. E¡ects on heart lipid levels
The amounts of total lipid, triacylglycerol, total phospho-
lipid, phosphatidylinositol, phosphatidylethanolamine and
cardiolipin contained in the heart of the 8-week-old JVS
mouse group were signi¢cantly greater than those in the con-
trol heart (Table 2). Treatment of JVS mice with L-carnitine
resulted in a decrease in these amounts which were not
signi¢cantly di¡erent from those of the control group.
3.3. Carnitine levels in heart during L-carnitine treatment
Heart free carnitine, short-chain acyl-carnitine and long-
chain acyl-carnitine levels in untreated JVS mice were signi¢-
cantly lower than in the control mice (Fig. 1). Treatment of
JVS mice with L-carnitine did not result in a signi¢cant rise in
these parameter.
3.4. Time course of blood free carnitine levels after an
intraperitoneal injection of L-carnitine
The time course of free carnitine levels after an intraperito-
neal injection of L-carnitine was simulated in control (Fig. 2A)
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Fig. 1. Myocardial carnitine contents in control, treated JVS and
non-treated JVS mice at 2, 4 and 8 weeks of age. JVS mice were
treated with L-carnitine from day 10 after birth until 4 weeks or
8 weeks of age, respectively. Concerning the data at 4 weeks of age,
JVS mice received no treatment, whereas JVS/N mice at 8 weeks of
age were treated with L-carnitine from day 10 after birth until day
21^25. Results are means þ S.D. of 4^19 independent measurement.
*P6 0.05; **P6 0.01; ***P6 0.001 compared with control.
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and JVS mice (Fig. 2B). Before injection, free carnitine levels
in plasma were 46.63 nmol/ml in control mice and 19.74 nmol/
ml in JVS mice. The peak concentration was 1548 nmol/ml at
11 min in control mice and 1570 nmol/ml at 11 min in JVS
mice. The half-time for the disappearance was 19 min in con-
trol mice and 22 min in JVS mice.
3.5. Short-term changes in heart carnitine levels after an
intraperitoneal injection of L-carnitine
Free carnitine, short-chain acyl-carnitine and long-chain
acyl-carnitine levels in hearts were signi¢cantly lower in the
JVS mouse group, compared to the control group, when
tested using repeated ANOVA (P6 0.001) (Fig. 3). In the
case of the control group, the free carnitine levels tended to
decrease after the injection. The decrease was statistically sig-
ni¢cant at 30 min after the injection. The long-chain acyl-
carnitine level increased with time after the injection, and
the increase was statistically signi¢cant at 15 and 30 min after
the injection. The total carnitine level remained unchanged.
Among JVS mice, the free carnitine level and the long-chain
acyl-carnitine level remained unchanged after the injection.
The short-chain acyl-carnitine level and the total carnitine
level were signi¢cantly higher at l5 min after the injection,
compared to their pre-injection levels.
4. Discussion
In an earlier study, we reported that the C3H/JVS mouse
develops cardiomegaly, as characterized by hypertrophy of
both ventricles and the septum [17]. In addition, it has pre-
viously been reported that administration of L-carnitine to this
JVS mouse resulted in reduction of cardiomegaly [16].
In the present study, we found the B6/JVS mouse also de-
velops a similar cardiomegaly and also responds to carnitine
therapy. In short, this study clearly demonstrates that a
mouse with a di¡erent background, if only the mutant gene
is defective, is capable of exhibiting cardiomegaly and has the
potential to respond to therapeutic intervention.
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Table 1
Heart weight, body weight and heart weight/body weight ratio for JVS and control mice at 2, 4 and 8 weeks of age
(A) Control (B) JVS/T (C) JVS/N P
A vs. B A vs. C B vs. C
Heart weight (g)
2 weeks 0.05 þ 0.01 (11) ^ 0.09 þ 0.01 (4) ^ 6 0.01 ^
4 weeks 0.09 þ 0.02 (11) 0.11 þ 0.02 (7) 0.07 þ 0.04 (12) n.s. 6 0.05 6 0.01
8 weeks 0.12 þ 0.03 (9) 0.16 þ 0.02 (9) 0.23 þ 0.01 (7) 6 0.01 6 0.001 6 0.001
Body weight (g)
2 weeks 7.31 þ 1.21 (11) ^ 6.84 þ 0.66 (4) ^ n.s. ^
4 weeks 16.04 þ 3.49 (11) 16.14 þ 3.22 (7) 5.00 þ 1.63 (12) n.s. 6 0.001 6 0.001
8 weeks 23.39 þ 4.44 (9) 22.29 þ 3.61 (9) 18.45 þ 1.76 (7) n.s. 6 0.05 6 0.05
Heart weight/body weightU1033
2 weeks 6.9 þ 1.1 (11) ^ 12.0 þ 1.4 (5) ^ 6 0.001 ^
4 weeks 5.7 þ 0.6 (11) 7.1 þ 1.1 (7) 13.1 þ 2.1 (12) n.s. 6 0.001 6 0.001
8 weeks 5.1 þ 0.6 (9) 7.3 þ 0.8 (9) 12.5 þ 0.9 (7) 6 0.001 6 0.001 6 0.001
JVS/T: JVS mice were treated with L-carnitine from day 10 after birth until 4 weeks or 8 weeks of age. JVS/N: concerning the data at 4 weeks of
age, JVS mice received no treatment, whereas JVS/N at 8 weeks of age were treated with L-carnitine from day 10 after birth until days 21^25.
Data are means þ S.D.
The number of animals used is shown in parentheses.
Fig. 2. Time courses of free carnitine levels in plasma after an intraperitoneal injection of L-carnitine. L-Carnitine was administered to control
(A) or JVS mice (B) at a dose of 1 Wmol/g body weight. Mean values from 3^10 samples are plotted. Solid curves are simulated by a one-com-
partment model with ¢rst order absorption [20].
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Since free carnitine is a substrate for carnitine acetyltrans-
ferase (CAT) and carnitine palmitoyltransferase, a decrease in
the free carnitine level within the myocardium would be pre-
dicted to result in a disturbance in intracellular lipid metabo-
lism [28^31]. We therefore analyzed the total lipid content and
its composition. The results showed that the JVS mouse, com-
pared to the control, had higher levels of total lipid, triacyl-
glycerol, total phospholipid, phosphatidylinositol, phosphati-
dylethanolamine and cardiolipin. The levels of all of these
tended to decrease to normal control levels as the result of
administration of L-carnitine.
Since the administration of L-carnitine was found to have
such an obvious preventive e¡ect, we then examined whether
any increase in the level of carnitine within the heart existed.
Initially, untreated JVS mice, compared to the control, were
found to have signi¢cantly lower contents of free carnitine,
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Fig. 3. Time courses of heart carnitine levels after an intraperitoneal injection of L-carnitine. Carnitine contents in control mice and JVS mice
are plotted at 0 min, 15 min and 30 min after an intraperitoneal injection of L-carnitine at a dose of 1 Wmol/g body weight. Results are
means þ S.D. of 4^10 independent measurements. *P6 0.05; **P6 0.01 compared with control.
Table 2
Pro¢le of lipids in heart tissue of control and JVS mice at 8 weeks of age
(A) Control (B) JVS/T (C) JVS/N P
A vs. B A vs. C B vs. C
Total lipid 26.98 þ 7.26 (6) 40.12 þ 10.18 (6) 57.96 þ 19.39 (6) n.s. 6 0.01 6 0.05
Triacylglycerol 5.24 þ 3.63 (7) 8.18 þ 4.77 (9) 23.39 þ 20.44 (9) n.s. 6 0.05 6 0.05
Cholesterol 4.13 þ 0.80 (10) 3.65 þ 0.58 (8) 4.03 þ 0.33 (8) n.s. n.s. n.s.
Total phospholipid 16.65 þ 6.68 (11) 20.78 þ 6.18 (10) 29.35 þ 9.06 (10) n.s. 6 0.001 6 0.05
Phosphatidylinositol 0.62 þ 0.14 (9) 0.88 þ 0.33 (6) 1.18 þ 0.45 (6) n.s. 6 0.01 n.s.
Phosphatidylserine 0.68 þ 0.33 (9) 0.77 þ 0.46 (6) 0.69 þ 0.47 (6) n.s. n.s. n.s.
Phosphatidylcholine 8.36 þ 2.45 (9) 8.86 þ 3.09 (6) 11.97 þ 3.67 (6) n.s. n.s. n.s.
Phosphatidylethanolamine 5.78 þ 1.92 (9) 7.62 þ 3.34 (6) 12.73 þ 4.39 (6) n.s. 6 0.001 6 0.05
Cardiolipin 2.81 þ 0.93 (9) 3.33 þ 1.15 (6) 6.23 þ 2.42 (6) n.s. 6 0.01 6 0.05
Sphingomyelin 0.67 þ 0.17 (9) 0.40 þ 0.28 (6) 0.50 þ 0.14 (6) n.s. n.s. n.s.
Units: Wg/mg weight. Data are means þ S.D.
JVS/T: JVS mice were treated with L-carnitine from day 10 after birth until 8 weeks of age. JVS/N: JVS mice were treated with L-carnitine from
day 10 after birth until days 21^25, after which no treatment was received.
The number of animals used is shown in parentheses.
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short-chain acyl-carnitine, and long-chain acyl-carnitine at
weeks 2, 4 and 8. This result was the same as observed in
the C3H/JVS mouse [10].
The heart carnitine content of the JVS mouse during the
treatment tended to be higher at 24 h after the ¢nal admin-
istration, compared to the untreated JVS mouse, but this in-
crease was not statistically signi¢cant. To examine the acute
e¡ect of L-carnitine, the free carnitine levels in heart was
measured at 15 and 30 min after the injection of L-carnitine,
when the free carnitine level in the blood was still maintained
at a higher level (Fig. 2). As shown in Fig. 3, the level of free
carnitine in heart was not altered signi¢cantly before and after
administration. It is possible to assume that the free carnitine
level in the heart is increased when the administration of
L-carnitine prevents cardiomegaly in a JVS mouse. However,
contrary to this prediction, as shown in Fig. 3, the increase of
free carnitine level in the heart was negligible even in the case
of animals which showed a high level of free carnitine after
injection. These results question the direct role of free carni-
tine in its cardioprotective e¡ect in JVS mice.
In contrast, the short-chain acyl-carnitine level was in-
creased as shown in Fig. 3. This increase was not predicted.
Short-chain acyl-carnitine is a general name for acyl-carnitine
which contain an acyl group of less than 10 carbons [24].
Although we did not analyze the composition of short-chain
acyl-carnitine in the present study, short-chain acyl-carnitine
eventually serves as a good substrate for the TCA cycle, there-
by contributing to the amelioration of the disorders in heart
energy metabolism. For example, acetyl-carnitine and pro-
pionyl-carnitine enter the mitochondria via transport through
the mitochondrial membrane, these compounds are ¢nally
converted to citrate and succinate, respectively [32]. In partic-
ular, it has been well demonstrated, in numerous experimental
models of heart failure resulting from coronary artery ligation
[33], pressure overload [34] and volume overload [35], that the
administration of L-propionyl-carnitine improves cardiac
function. L-Acetyl-carnitine can also improve the recovery of
cardiac output in the isolated perfused rat heart [36]. Thus, an
intraperitoneal injection of L-carnitine is expected to result in
a bene¢cial e¡ect. With daily injection of L-carnitine as were
used in the treated group, this e¡ect is repeated and might
lead to the prevention of cardiomegaly. CAT, the biosynthetic
enzyme for short-chain acyl-carnitine, is abundant in heart
[32,37]. Therefore, the JVS mouse heart o¡ers an environment
in which short-chain acyl-carnitine level can be increased.
However, additional studies will be required in order to elu-
cidate the precise mechanism for the increase in short-chain
acyl-carnitine levels.
In summary, the administration of L-carnitine to the JVS
mouse, an animal model of primary carnitine de¢ciency, re-
sulted in an increase in the short-chain acyl-carnitine levels
within the heart. This compound appears to be a key com-
pound which might explain the simultaneous manifestation of
therapeutic e¡ects.
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